Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S423000, C514S429000, C548S524000, C548S538000, C548S565000, C548S571000, C548S577000, C546S208000
Reexamination Certificate
active
10531495
ABSTRACT:
The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
REFERENCES:
patent: 3644414 (1972-02-01), Helsey et al.
patent: 6057342 (2000-05-01), Fevig et al.
patent: 6440686 (2002-08-01), Sakowicz
Marcus et al. Journal of Biological Chemistry, 2005, 280, p. 11569.
M. J. Breslin, et al., Database CALPUS on STN, DN:139:307756 (2003).
M. Bujard, et al., Tetrahedron Letters (40), pp. 8785-8788 (1999).
M.J.S. Carpes, et al., Synlett., No. 7, pp. 1037-1039 (2000).
C. Sonesson, et al., J. Org. Chem. 1996, vol. 61, p. 4756-4763.
N. Iwasawa, et al., J. Org. Chem. 1998, vol. 63, p. 3164-3165.
N. Iwasawa, et al., J. Org. Chem. 1997, vol. 62, p. 1918-1919.
R. Mison, et al., J. Chem. Research(S), 1989, 126-127.
A. Boukhari, et al., J. Cryst. Spect. Res., vol. 19, Iss. 3, 1989, p. 603-621.
N. Moss, et al., J. Med. Chem., vol. 36 (20) pp. 3005-3009 (1993).
M. Fraley, et al., Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters (2006).
R. Garbaccio, et al., Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorganic & Medicinal Chemistry Letters (2006).
Breslin Michael J.
Coleman Paul J.
Cox Christopher D.
Hartman George D.
Mariano Brenda J.
Beeler Nicole M.
Chu Yong
McKane Joseph K.
Merck & Co. , Inc.
Muthard David A.
LandOfFree
Mitotic kinesin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mitotic kinesin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mitotic kinesin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3851275